CLOVIS EDUARDO SANTOS GALVAO

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Assunto: Allergy ×

Resultados de Busca

Agora exibindo 1 - 9 de 9
  • article 23 Citação(ões) na Scopus
    Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial
    (2022) LANGER, Sarah Sella; CARDILI, Renata Nahas; MELO, Janaina Michelle Lima; FERRIANI, Mariana Paes Leme; MORENO, Adriana Santos; DIAS, Marina Mendonca; BUENO-FILHO, Roberto; POCENTE, Renata Helena Candido; ROXO-JUNIOR, Persio; SILVA, Jorgete; VALERA, Fabiana Cardoso Pereira; COELHO, Eduardo Barbosa; GALVAO, Clovis Eduardo Santos; CARMONA, Fabio; ARAGON, Davi Casale; ARRUDA, Luisa Karla
    BACKGROUND: Sensitization to house dust mites (HDMs) is frequent in patients with atopic dermatitis. OBJECTIVE: To investigate the efficacy of sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus extract in patients with atopic dermatitis sensitized to HDM. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled 91 patients 3 years or older, with SCORing Atopic Dermatitis (SCORAD) score greater than or equal to 15 and positive skin test result and/or IgE to D pter-onyssinus. Patients were stratified according to age (<12 and >= 12 years) to receive HDM SLIT or placebo for 18 months. Primary outcome was a greater than or equal to 15-point decrease in SCORAD score. Secondary outcomes were decreases in SCORAD and objective SCORAD, Eczema Area and Severity Index, visual analog scale for symptoms, and pruritus scale scores; Investigator's Global Assessment 0/1; and decrease greater than or equal to 4 points in Dermatology Life Quality Index. Background therapy was maintained. RESULTS: A total of 66 patients completed the study (35 HDM SLIT, 31 placebo). After 18 months, 74.2% and 58% of patients in the HDM SLIT group and the placebo group, respectively, showed greater than or equal to 15-point decrease in SCORAD score (relative risk, 1.28; 95% CI, 0.89-1.83). Significant SCORAD score decreases from baseline of 55.6% and 34.5% in HDM SLIT and placebo groups (mean difference, 20.4; 95% CI, 3.89-37.3), significant objective SCORAD score decreases of 56.8% and 34.9% in HDM SLIT and placebo groups (mean difference, 21.3; 95% CI, 0.66-41.81), and more patients with Investigator's Global Assessment 0/1 in the HDM SLIT group as compared with the placebo group (14 of 35 vs 5 of 31; relative risk, 2.63; 95% CI, 1.09-6.39) were observed at 18 months. CONCLUSIONS: Our results suggest that HDM SLIT may be effective in HDM-sensitized patients as an add-on treatment for atopic dermatitis. (C) 2021 The Authors.
  • conferenceObject
    Inflammatory cell response, functional and biochemical features of the airways of professional cleaning workers upon exposure in the workplace
    (2017) LIMA, Cynthia F. Mafra; SARAIVA, Beatriz M.; KALIL, Jorge; CASTRO, Fabio M.; GALVAO, Clovis Eduardo S.
  • article 2 Citação(ões) na Scopus
    Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study
    (2023) MASPERO, Jorge F.; CARDONA, Guido; SCHONFFELDT, Patricia; TOLCACHIER, Alberto; GONZALEZ-DIAZ, Sandra N.; YANEZ, Anahi; GALVAO, Clovis E.; MSIHID, Jerome; GALL, Rebecca; SIDDIQUI, Shahid; ROWE, Paul J.; DENIZ, Yamo; JACOB-NARA, Juby A.; DJANDJI, Michel
    Objective While advances in asthma care have been made in Latin America, there is still a large unmet need in patients with uncontrolled asthma. This post hoc analysis of the QUEST study assessed safety and efficacy of dupilumab in the subgroup of patients enrolled in Latin American countries with a type 2 inflammatory asthma phenotype (blood eosinophils >= 150cells/mu L or FeNO >= 25ppb). Methods LIBERTY ASTHMA QUEST (NCT02414854) was a phase 3, multinational, randomized, double-blind, placebo-controlled study in patients with uncontrolled, moderate-to-severe asthma. Eligible patients >= 12 years of age were randomized in a 2:2:1:1 ratio to receive 52 weeks of add-on subcutaneous dupilumab 200 or 300 mg every 2 weeks or matched-volume placebos. Pre-specified co-primary efficacy endpoints were the annualized rate of severe exacerbations during the treatment period and the change from baseline in pre-bronchodilator FEV1 at treatment week 12. Asthma control, changes in asthma biomarker levels, and dupilumab safety were also evaluated. Results 530 (27.9% of the overall QUEST population; dupilumab: 353, placebo: 177) Latin-American patients were recruited; 420 (79.2%) had a type 2 inflammatory asthma phenotype. Dupilumab vs placebo reduced the annualized rate of severe exacerbations by 52.7% (P < 0.001) and increased pre-bronchodilator FEV1 at week 12 by 0.15 L (P < 0.001), in the type 2 population. Safety was consistent with the known dupilumab safety profile. Conclusions Consistent with the results in the overall population, dupilumab reduced the risk of severe asthma exacerbations and improved lung function in Latin American patients with uncontrolled, moderate-to-severe asthma and a type 2 phenotype.
  • conferenceObject
    Comparative Evaluation Of Pulmonary Function Tests In Professional Cleaners While Exposed To The Occupational Workplace And After The Vacation Period
    (2019) LIMA, Cynthia Mafra Fonseca de; HERNANDES, Giovanna Hernandes y; ALGRANTI, Eduardo; MACAIRA, Elayne de Fatima; KALIL, Jorge; CASTRO, Fabio M.; GALVO, Clovis E. S.
  • article 20 Citação(ões) na Scopus
    Allergic reactions to manioc (Manihot esculenta Crantz): Identification of novel allergens with potential involvement in latex-fruit syndrome
    (2011) SANTOS, Keity Souza; GALVAO, Clovis Eduardo; GADERMAIER, Gabriele; RESENDE, Virginia Maria Ferreira; MARTINS, Carlo de Oliveira; MISUMI, Denise Shimbo; YANG, Ariana Campos; FERREIRA, Fatima; PALMA, Mario Sergio; KALIL, Jorge; CASTRO, Fabio Fernandes Morato
  • conferenceObject
    Local production of IgE and other immune mediators in the nasal lavage fluid of allergic rhinitis patients before and after specific immunotherapy with Dermatophagoides pteronyssinus
    (2017) TEIXEIRA, Adriana Rodrigues; SARAIVA, Beatriz M.; KALIL, Jorge; CASTRO, Fabio M.; GALVAO, Clovis Eduardo S.
  • article 3 Citação(ões) na Scopus
    Good clinical practice recommendations in allergen immunotherapy: Position paper of the Brazilian Association of Allergy and Immunology-ASBAI
    (2022) AARESTRUP, Fernando Monteiro; TAKETOMI, Ernesto Akio; GALVAO, Clovis Eduardo Santos; GAGETE, Elaine; ARRUDA, Anna Caroline Nobrega Machado; ALVES, Gil Bardini; LIRA, Georgia Veras de Araujo Gueiros; GONCALVES, Marcos Reis; MIZIARA, Mariana Graca Couto; CASADO, Sidney Souteban Maranhao; CURI, Simone Valladao; PEREIRA, Veridiana Aun Rufino; SALES, Valeria; SOLE, Dirceu; RUBINI, Norma de Paula Motta; SARINHO, Emanuel Savio Cavalcanti
    Background: Allergen Immunotherapy (AIT) represents one of the pillars in the treatment of allergic diseases. AIT is the only therapeutic strategy with curative potential, promoting the reduc-tion of drug use and long-term symptom control even after the end of the treatment. The European Academy of Allergy, Asthma and Immunology (EAACI) guidelines, position papers of World Allergy Organization (WAO), and the US Practice Parameters are the leading official documents that set scientific standard for the use of AIT in the world. The use of AIT in Brazil has specific regional conditions due to the pattern of allergen sensitization, as well as genetic, socioeconomic, and cul-tural characteristics, climate conditions, and the availability of allergenic extracts. The most prevalent house dust mites are Dermatophagoides pteronyssinus, Dermatophagoides farinae and their aller-gens have the highest clinical relevance. Blomia tropicalis is also very frequent. This position paper has been prepared by the Brazilian Association of Allergy and Clinical Immunology (ASBAI) Task -force on AIT for respiratory allergy and Hymenoptera venom allergy.Objective: According to the current scientific literature adapted to the Brazilian reality, this po-sition paper aims to establish the main recommendations for the good clinical practice parameters for AIT in Brazil.Methods: A systematic review using the Pub Med and Cochrane databases was performed, and the websites of major allergy and immunology organizations were consulted. The research was limited to English language literature and was conducted between March 30, 2002, and March 30, 2022. The terms used for the research were: Allergen Immunotherapy, sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), venom-specific immunotherapy (VIT), and allergen extract.Results: The several recommendations that establish the clinical practices for AIT recommended by the main Allergy, Asthma and Immunology world organizations were analyzed and adapted to the Brazilian situation.Conclusion: This position paper establishes the main recommendations for the effective clinical practice of AIT in Brazil, using current knowledge of evidence-based medicine and precision medicine.
  • conferenceObject
  • conferenceObject
    Multi-sensitization to hymenoptera venoms in a group of Brazilian patients
    (2015) AMICIS, K. M. De; WATANABE, A. S.; GALVAO, C. E.; FIGO, D. D.; SANTOS-PINTO, J. R. A. dos; PALMA, M. S.; CASTRO, F. F.; KALIL, J.; FERREIRA-BRIZA, F.; GADERMAIER, G.; SANTOS, K. S.